Financial reports
10-Q
2024 Q3
Quarterly report
6 Nov 24
10-Q
2024 Q2
Quarterly report
7 Aug 24
10-Q
2024 Q1
Quarterly report
8 May 24
ARS
2023 FY
Annual report to shareholders
26 Apr 24
10-K
2023 FY
Annual report
21 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
10-Q
2023 Q1
Quarterly report
10 May 23
10-K
2022 FY
Annual report
22 Mar 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
Current reports
8-K
Context to obtain exclusive development and commercialization rights to BA3362
23 Sep 24
8-K
Amendments to Articles of Incorporation or Bylaws
17 Sep 24
8-K
Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors
4 Sep 24
8-K
Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95
10 Jul 24
8-K
Submission of Matters to a Vote of Security Holders
14 Jun 24
8-K
Context Therapeutics Announces $100 Million Private Placement
2 May 24
8-K
Important Regulatory Milestone Supports Next Phase of CTIM-76 Development
1 Apr 24
8-K
Amendments to Articles of Incorporation or Bylaws
21 Mar 24
8-K
March 2024 Corporate Presentation Advancing Medicines for Solid Tumors
6 Mar 24
8-K
Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76
31 Oct 23
Registration and prospectus
S-3
Shelf registration
6 Nov 24
424B3
Prospectus supplement
31 May 24
S-3
Shelf registration
24 May 24
D
$100.00 mm in equity / securities to be acquired, sold $99.99 mm, 26 investors
16 May 24
S-8
Registration of securities for employees
21 Mar 24
S-8
Registration of securities for employees
22 Mar 23
424B3
Prospectus supplement
14 Nov 22
POS AM
Prospectus update (post-effective amendment)
9 Nov 22
S-3
Shelf registration
9 Nov 22
424B3
Prospectus supplement
9 Nov 22
Proxies
DEFA14A
Additional proxy soliciting materials
24 Jul 24
DEF 14A
Definitive proxy
24 Jul 24
PRE 14A
Preliminary proxy
12 Jul 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
DEFA14A
Additional proxy soliciting materials
6 Apr 23
DEF 14A
Definitive proxy
6 Apr 23
PRE 14A
Preliminary proxy
27 Mar 23
DEFA14A
Additional proxy soliciting materials
4 Apr 22
DEF 14A
Definitive proxy
4 Apr 22
Other
EFFECT
Notice of effectiveness
3 Jun 24
EFFECT
Notice of effectiveness
17 Nov 22
EFFECT
Notice of effectiveness
14 Nov 22
CORRESP
Correspondence with SEC
14 Nov 22
UPLOAD
Letter from SEC
14 Nov 22
EFFECT
Notice of effectiveness
8 Apr 22
EFFECT
Notice of effectiveness
17 Dec 21
CORRESP
Correspondence with SEC
14 Dec 21
UPLOAD
Letter from SEC
13 Dec 21
EFFECT
Notice of effectiveness
20 Oct 21
Ownership
SC 13G/A
Hudson Bay Capital Management LP
6 Nov 24
4
Karen L. Smith
5 Sep 24
3
Karen L. Smith
5 Sep 24
4
Luke Nathaniel Walker
5 Sep 24
3
Luke Nathaniel Walker
5 Sep 24
4
Ullmann Claudio Dansky
1 Aug 24
3
Ullmann Claudio Dansky
1 Aug 24
4
Jennifer Evans Stacey
14 Jun 24
4
Philip W. Kantoff
14 Jun 24
4
Linda West
14 Jun 24